Vaccine Therapy in Treating Patients With Newly Diagnosed Advanced Colon Polyps (NCT02134925)
Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Vaccine in Patients With Newly Diagnosed Advanced Adenomas
🩺 Plain-English Summary (8th-Grade Level)
This randomized phase II clinical trial studies how well MUC1 peptide-poly-ICLC adjuvant vaccine works in treating patients with newly diagnosed advanced colon polyps (adenomatous polyps). Adenomatous polyps are growths in the colon that may develop into colorectal cancer over time. Vaccines made from peptides may help the body build an effective immune response to kill polyp cells. MUC1 peptide-poly-ICLC adjuvant vaccine may also prevent the recurrence of adenomatous polyps and may prevent the development of colorectal cancer.
Who can join: Review the eligibility criteria below.
Location: Massachusetts General Hospital Cancer Center — Boston, Massachusetts
Age range: 40 Years to 70 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (7 Sites)
- Massachusetts General Hospital Cancer Center — Boston, Massachusetts
- Mayo Clinic in Rochester — Rochester, Minnesota
- Kansas City Veterans Affairs Medical Center — Kansas City, Missouri
- Thomas Jefferson University Hospital — Philadelphia, Pennsylvania
- Fox Chase Cancer Center — Philadelphia, Pennsylvania
- UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania
- University of Puerto Rico — San Juan,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Colorectal Adenoma
- Linaclotide in Treating Patients With Stages 0-3 Colorectal Cancer — Philadelphia, Pennsylvania
- Aspirin in Preventing Colorectal Cancer in Patients With Colorectal Adenoma — Nashville, Tennessee
- Evaluation of Gixam's Performance in a FIT Negative Population — Portland, Oregon
Explore by condition: All Colorectal Adenoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.